Impact of PC/BCP Mutations on Seroconversion and Relapse in HBeAg-Positive Chronic Hepatitis B Patients Treated with Nucleoside Analogues

PC/BCP mutations are independent risk factors for poor NA response and high relapse rates in HBeAg-positive CHB patients. Patients with these mutations should be managed as "occult HBeAg-negative CHB" to avoid premature treatment discontinuation. Routine PC/BCP mutation testing is recommended to guide individualized treatment duration in HBeAg-positive CHB patients.